SR-T100 Gel Efficacy & Safety Study for Vulva Pre-cancerous Lesions & Cutaneous Condyloma
A Pilot Study to Assess the Efficacy & Safety of Topical SR-T100 Gel in the Treatment of Human Vulva Pre-cancerous Lesions (Vulvar Intraepithelial Neoplasia; VIN) & Cutaneous Condyloma(External Genital Warts; EGWs)
Sponsor: G&E Herbal Biotechnology Co., LTD
Listed as NCT01676792, this EARLY_PHASE1 trial focuses on Genital Warts and Vulvar Intraepithelial Neoplasia and remains completed. Sponsored by G&E Herbal Biotechnology Co., LTD, it has been updated 8 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Dec 2025 — Present [monthly]
Completed EARLY_PHASE1
-
Sep 2025 — Dec 2025 [monthly]
Completed EARLY_PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Completed EARLY_PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed EARLY_PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed EARLY_PHASE1
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed EARLY_PHASE1
-
Feb 2017 — Jun 2018 [monthly]
Completed EARLY_PHASE1
Phase: Phase 0 → EARLY_PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Completed Phase 0
First recorded
Apr 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- G&E Herbal Biotechnology Co., LTD
- National Cheng-Kung University Hospital
For direct contact, visit the study record on ClinicalTrials.gov .